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The authors respond to the article by H. F. Coelho, P. H. Canter, and E. Ernst (2007), which reviewed
the current status of mindfulness-based cognitive therapy (MBCT). First, they clarify the randomization
procedures in the 2 main MBCT trials. Second, they report posttreatment and follow-up data to show that
trial participants allocated to “treatment as usual” did not become worse. Third, they discuss which
experimental designs are better for identification of the active component of treatment. Finally, they
report reanalyses of the 2 main MBCT trials with multilevel modeling that corrected for intragroup
correlations. These analyses reinforce the original findings: For patients with 3 or more previous
episodes, MBCT significantly reduced the risk of a further episode of depression and significantly
decreased mean scores on the Beck Depression Inventory (A. T. Beck, C. H. Ward, M. Mendelson, J.
Mock, & J. Erbaugh, 1961) after treatment.
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Mindfulness-based cognitive therapy (MBCT) was developed as
a manualized group-skills training program that would address
vulnerability between episodes of recurrent major depression (Se-
gal, Williams, & Teasdale, 2002; Williams, Teasdale, Segal, &
Kabat-Zinn, 2007). It was derived from a model of cognitive
vulnerability to depressive relapse (Segal, Williams, Teasdale, &
Gemar, 1996; Teasdale, 1988; Teasdale, Segal, & Williams, 1995);
according to the model, individuals who have previously experi-
enced episodes of major depression differ from those who have not
in the patterns of negative thinking that become activated in mildly
depressed moods. For these individuals, small downward mood
shifts are more likely to produce recurrence, because they activate
patterns of self-denigrating depressogenic thinking similar to those
that prevailed in preceding episodes.
MBCT integrates aspects of cognitive–behavioral therapy for
depression (Beck, Rush, Shaw, & Emery, 1979) into the
mindfulness-based stress reduction (MBSR) program developed
by Kabat-Zinn (1990). MBCT teaches patients who are currently
in remission from recurrent major depression to become more
aware of, and to relate differently to, their thoughts, feelings, and
bodily sensations. For example, patients are encouraged to relate to
thoughts and feelings as passing events in the mind, rather than to
identify with them or treat them as accurate representations of
reality. MBCT teaches skills that allow individuals to disengage
from habitual (“automatic”) dysfunctional cognitive routines, in
particular, depression-related ruminative thought patterns, as a
way to reduce future risk of relapse and recurrence of depression.
The article by Coelho, Canter, and Ernst (2007) gave a good
account of the current empirical status of this approach and high-
lighted the two main randomized controlled trials (RCTs). These
trials (Ma & Teasdale, 2004; Teasdale et al., 2000) reported that,
for patients with a history of three or more episodes, MBCT
substantially reduced the rate of recurrence over the following 12
months.
Coelho et al. (2007) rightly pointed out that many important
questions were left unanswered by these trials. It could be argued
that the timing of their review of MBCT was premature. Despite
recent promising evidence (Barnhofer et al., 2007; Kenny & Wil-
liams, 2007; Kingston, Dooley, Bates, Lawlor, & Malone, 2007),
there simply have not yet been sufficient randomized trials for us
to form a definitive view of the efficacy of MBCT. Specifically, if
one applies the principles of Onken and Rounsaville (Onken,
Blaine, & Battjes, 1997; Rounsaville, Carroll, & Onken, 2001),
who describe a model for research on the development of novel
behavioral therapies, one sees that MBCT remains a rather new
treatment that has not had sufficient time to accrue a sufficient
body of work to provide all the nuances expected by Coelho et al.
The Onken and Rounsaville approach for developing novel treat-
ments involves three progressive stages that guide the process of
treatment development in a manner informed by ever more com-
plex and rigorous tests of the novel protocol. At Stage 1, investi-
gators conduct pilot/feasibility studies, manual writing, training
program development, and adherence/fidelity measure develop-
ment. This process, described in detail in Segal et al. (2002) and
Segal, Teasdale, Williams, & Gemar (2002), took place during the
early 1990s.
Stage 2 consists of RCTs that evaluate efficacy and can include
investigation of mechanisms of action. The first trial was done
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zzzPsgiolePfrpbetween 1995 and 1998 and was published in 2000; the second
trial was published in 2004. Stage 3 research focuses on issues
such as treatment transportability and generalizability. Several
trials are in progress but have not yet been concluded. The Onken
and Rounsaville model for behavior therapies offers a blueprint for
treatment development that is widely accepted (e.g., at the Na-
tional Institutes of Health) and that guides the development of
evidence-based treatments.
With these criteria in mind, how can we best respond to the
points raised at this stage by Coelho et al. (2007)? In this article,
we seek to do three things. First, we briefly clarify the existing trial
data to answer the questions raised. Second, we discuss in more
detail the issues that arise for those designing the next generation
of trials. Third, in the light of Onken and Rounsaville’s criteria for
Stage 3, we show that there is at least one more important issue
that this domain of research needs to address in the future: the
problems that accompany use of traditional statistical analyses
when patients are treated in groups and that, thus, may influence
each other’s outcomes.
Issues in Trials of MBCT
Details of Previous Trials
Coelho et al. (2007) mentioned lack of clarity in randomization
procedures in Teasdale et al. (2000) and Ma and Teasdale (2004).
These studies gave the following details:
Randomization involved treatment sites faxing patient initials, date of
birth, gender, date of assessment, and details of number and recency
of previous episodes of depression to a central independent allocator.
Information was sent for groups of eligible patients at a time. The
central allocator randomly allocated patients to treatment condition,
gave each a study number, and faxed the allocations and study
numbers back to treatment sites. (Teasdale et al., 2000, p. 617)
Randomization of patients to treatment condition was by a statistician,
who was not part of the research team, on receipt of the participant’s date
of birth, gender, date of assessment, number of previous episodes of
depression, and severity of last episode. (Ma & Teasdale, 2004, p. 32)
Thus, although the first of these trials began before the original
publication of the CONSORT guidelines for the conduct and
reporting of RCTs (Begg et al., 1996; updated by Moher, Schulz,
& Altman, 2001), both Teasdale et al. (2000) and Ma and Teasdale
(2004) kept random allocation concealed from trial participants
and staff before recruitment, a key requirement of these guidelines.
Second, Coelho et al. (2007) wondered whether more data on
mood variables (e.g., Beck Depression Inventory [BDI] scores;
Beck, Ward, Mendelson, Mock, & Erbaugh, 1961) would have
been beneficial. Such data might, for instance, indicate that par-
ticipants who were allocated to the control arm that received
“treatment as usual” (TAU) suffered from “resentful demoraliza-
tion” (Cook & Campbell, 1979) at not receiving treatment. We
have therefore checked the mean BDI scores for the 66 participants
allocated to TAU (in trials of both Teasdale et al., 2000, and Ma
& Teasdale, 2004), who had at least three previous episodes and
valid BDI scores at each follow-up point. Their scores were as
follows: baseline (M  11.8, SD  8.5), immediate posttreatment
(or equivalent; M  12.1, SD  8.1), and final follow-up (M 
11.9, SD  9.5). Repeated-measures analysis showed no signifi-
cant differences between these time points (p  .95). Thus, there
is no evidence that the mood of those not receiving treatment
worsened during the trial. Although we cannot rule out the possi-
bility that resentful demoralization prevented an improvement that
would otherwise have occurred in the control group, it is very
unlikely to account for the large treatment effect on both BDI and
time to recurrence described later in this article. We are grateful to
Coelho et al. for the opportunity to return to these data to clarify
this point.
What Control Treatment?
Coelho et al. (2007) rightly pointed out that trials of MBCT have
compared the effects of adding MBCT to TAU only with the
effects of TAU alone. So, these trials have not been able to control
either for the effects of the considerable psychological education
component of MBCT or for nonspecific factors, such as group
affiliation and therapist support. As Teasdale et al. (2000, p. 617)
mentioned this limitation explicitly, Coelho et al. are right to
advocate that future RCTs need to compare MBCT not only with
TAU but with a group-based therapy that has equal plausibility and
acceptability to patients.
When one selects the appropriate control treatment, several
choices are available. One option is comparison of the MBCT
package with an effective group-based package (e.g., group-based
CBT) that requires comparable attendance and homework. This
option has the advantage of comparing the treatment of interest
with a practical alternative but has two disadvantages. First, if one
aims to prevent recurrence, it is important to recognize that many
comparable treatments are intended to treat acute depression rather
than to prevent relapse and thus may have smaller effects on
relapse (Bockting et al., 2005). Second, whatever the outcome of
such a comparison, it could not yield an unambiguous answer to
the scientific question we wish to answer: Which component of
relapse-prevention treatment is critical to success? Another option
is to assess mediating variables (Kraemer, Wilson, Fairburn, &
Agras, 2002), but this approach suffers from multicollinearity and
thus ambiguity.
A better choice than either practical alternatives or mediating
variables is use of a “dismantling” paradigm, in which the com-
parison treatment is identical to the experimental treatment except
for a critical component (cf. Jacobson et al., 1996). Given that the
most complex aspect of MBCT is intensive training in meditation,
in a dismantling design, the control treatment should follow the
group format of MBCT but should not include training in medi-
tation. This is the design we have chosen for our next trial of
MBCT, with recurrently depressed patients who are suicidal. The
control treatment is essentially the psychological education com-
ponent of MBCT; it will include the same number and length of
sessions as does MBCT, thus controlling for group and therapist
support, but will incorporate short educational presentations fol-
lowed by discussions instead of meditation training. Teaching will
cover learning about depression, links between thoughts and feel-
ings, and self-monitoring these links for signs of impending recur-
rence. This design will enable us to answer the key question: How
much any reduction in recurrence is attributable to training in
meditation rather than to group attendance, therapist support, and
psychoeducation. If we find no difference between psychoeduca-
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know that meditation is unnecessary.
However, all these designs require compromise. For example,
though psychoeducation includes self-monitoring and homework,
the dismantling design does not ensure equal homework, as med-
itation demands more homework. This design does not, therefore,
allow us to test the extent to which homework per se adds to the
effectiveness of treatment. Though other forms of homework, such
as exercise or relaxation, could substitute for meditation, this
substitution would create a new package that, like existing pack-
ages, cannot identify which component is essential for reducing
relapse. If MBCT is found to be more effective than is psycho-
education, therefore, further research will be needed to test
whether any homework would have enhanced effectiveness.
The Problem of Correlated Data in Group-Based
Interventions
Onken and Rounsaville have shown that a novel treatment
approach requires a staged approach. Those conducting treatment
research proceed by ensuring firm foundations before progressing
to the next stage. That is why it is beneficial to see whether, as
Coelho et al. (2007) have allowed us to do, even the foundations
are secure. However, one element of the foundational work that
was not addressed in the existing trials, nor by Coelho et al., is
potentially as or more threatening than are the issues they raise: the
problem of intragroup dependency. We raise this possibility here,
because it needs to be taken into account in the next round of
treatment research on MBCT.
Baldwin, Murray, and Shadish (2005) showed that, when treat-
ments such as CBT are administered in groups, the individuals
who receive the treatment may influence each other and thus create
dependencies between observations. One or two very depressed or
unmotivated participants could aggravate outcomes across their
group. By contrast, one or two very motivated individuals could
facilitate progress by their entire group. Despite this potential
dependence, virtually all of the trials reviewed by Baldwin et al.
(2005) involved statistical tests that treat each participant as an
individual, as if his or her outcomes were independent of those of
other participants. Both trials of MBCT also treated each partici-
pant as an individual for statistical analysis. However, intragroup
dependence violates the assumption of most traditional statistical
tests that observations are independent. Analyses that ignore the
resulting inflation in variance risk underestimating the standard
error of the treatment effect. The intragroup correlation (IGC)
measures the extent to which group membership has created such
dependency between observations. As Baldwin et al. (2005)
pointed out, IGC does not alter the underlying data but increases
the chance of Type 1 error when we claim to have found statistical
significance. The trials of MBCT may not have found a significant
effect of MBCT on relapse and recurrence, after all.
To address these issues, we returned to the data of Teasdale et
al. (2000) and Ma and Teasdale (2004) to (a) estimate IGCs; (b)
reanalyze those data by the unbiased statistical technique of mul-
tilevel modeling; (c) where possible, combine results from the two
studies; and (d) reassess the claim that MBCT reduces the risk of
relapse in participants with three or more previous episodes.
Reanalysis of MBCT Trials
We have reanalyzed data from both Teasdale et al. (2000) and
Ma and Teasdale (2004). These trials recruited participants in eight
and four cohorts, respectively, and allocated them to groups
(MBCT  TAU vs. TAU alone) within each cohort. However, in
the original analyses, cohorts were ignored; the analyses used
simple comparisons, based on chi-square tests, odds ratios (ORs),
and Cox regression, for relapse and t tests for the BDI. We have
responded to Baldwin et al. (2005) by including cohort and group
effects. We have combined findings for outcomes that were iden-
tical in both papers, after checking for homogeneity and goodness
of fit across trials. In addition, we have improved the precision of
comparisons by adjusting measured outcomes for baseline BDI.
In Table 1, we have allowed for cohort by pooling separate ORs
for each cohort and by testing whether ORs varied between co-
horts. This approach made little difference to the estimated OR, the
associated confidence interval (CI), or the significance of the
result. Furthermore, the homogeneity test showed that the OR was
consistent between cohorts. In other words, MBCT had essentially
the same effect in each cohort. The original articles also analyzed
survival (“time to relapse”) by Cox regression. We refined this
analysis by including both a cohort term and the initial BDI in the
model. Although initial BDI contributed significantly to all three
Cox regression models and strengthened the effect of MBCT, there
was no significant cohort effect. Indeed, cohort contributed less
than was expected by chance, in the equivalent of a negative IGC.
The analyses in Table 1 were possible because each MBCT group
was selected at random from a given cohort, with the unselected
control participants within that cohort forming a matched group.
Thus, the effect of MBCT consistently remained significant in all
reanalyses and achieved the highest level of significance and the
narrowest CIs in the combined analysis.
Although each cohort comprises an MBCT group and a control
group, we have estimated separate IGCs for each type of group
(see Table 2). Homogeneity within control groups is likely to be
demographic in origin (Cause A), but MBCT groups may be more
homogeneous if groups differed in their effectiveness (Cause B) or
if participants tended to follow the responses of others (Cause C).
In both studies and the combined analysis, however, all IGCs for
time to relapse were negative, which makes all three causes un-
likely. Although most but not all IGCs for BDI were positive but
generally small, there was no consistent tendency for IGCs to be
larger in either MBCT groups or control groups. Furthermore, no
IGC was significantly greater or less than zero. Thus, the data in
Table 2 show no evidence of any intragroup dependency.
Against this reassuring background, Table 3 shows the effect
of MBCT on BDI after treatment (adjusted for baseline BDI,
without and with consideration of cohort effects). These anal-
yses remained significant but showed increased significance
levels and wider confidence intervals, as we expected from
small positive estimates of IGC. Nevertheless, the combined
analyses are still highly significant and confirmed that MBCT
improves BDI by 4.7 points (95% CI, 2.1–7.3). Table 3 also
includes the reanalysis of time to relapse, which showed that
MBCT increases the average time to relapse by at least 18
weeks (95% CI, 10–27 weeks).
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Coelho et al. (2007) were right to propose that trials of
MBCT should be rigorous in the choice of control treatments,
randomization procedures, and methods of analysis. Baldwin et
al. (2005) were right to criticize the statistical analysis of most
trials of group therapy for the use of traditional methods that
assume independent observations.
We have shown how randomization in accordance with the
CONSORT guidelines (Moher et al., 2001) and use of a disman-
tling design can address the issues raised by Coelho et al. (2007).
In response to Baldwin et al. (2005), we have used multilevel
modeling to reanalyze participants within their groups and have
combined the findings of both of the main MBCT trials, in what is
sometimes described as a meta-analysis. We found that the IGC for
time to relapse was always negative and that the IGC for the BDI
after treatment was generally small, though positive. We conclude
that the attempt by Baldwin et al. (2005) to correct published
analyses by simulating intraclass correlation coefficients of up to
.3 was unduly pessimistic.
More important, we conclude that MBCT reduces the percent-
age of participants who relapse within 12 months from 70% to
39%, increases the average time to relapse by at least 18 weeks,
and decreases the BDI score after treatment by nearly 5 points (all
statistically significant at the 0.1% level). In short, our rigorous
reanalysis of both trials together has strengthened all of the orig-
inal findings.
We recommend that those planning trials of group-based ther-
apy in general and class-based mindfulness training in particular
Table 1
Relapse at 12 Months (Binary Outcome and Cox Regressions) by Trial
Variable
Teasdale et al.
(2000; n  105)
Ma & Teasdale
(2004; n  155) Both (N  260)
Number (%) relapsed
a
MBCT 22/55 (40) 10/28 (36) 32/83 (39)
Control 33/50 (66) 21/27 (78) 54/77 (70)
Simple analysis of ORs
OR (95% CI) 0.343 (0.155, 0.761) 0.159 (0.048, 0.523) 0.267 (0.138, 0.516)
Significance .008 .002  .001
Mantel-Haenzel analysis of ORs
b
Pooled OR (95% CI) 0.338 (0.152, 0.751) 0.165 (0.049, 0.552) 0.270 (0.139, 0.522)
Significance .008 .003  0.001
Significance of homogeneity test .381 .234 .318
Simple Cox regression
Hazard ratio (95% CI) 0.482 (0.281, 0.828) 0.278 (0.130, 0.597) 0.404 (0.260, 0.627)
Significance .008 .001  001
Cox regression
c
Hazard ratio (95% CI) 0.430 (0.246, 0.753) 0.261 (0.120, 0.569) 0.360 (0.230, 0.565)
Significance .003 .001  .001
Note. MBCT  mindfulness-based cognitive therapy; ORs  odds ratios; CI  confidence interval.
a These are intention to treat data, which include all patients randomized to MBCT whether they received treatment or not.
b With cohorts comprising two randomized groups as strata.
c Adjusting for cohort and initial Beck Depression Inventory (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961).
Table 2
Time to Relapse and Beck Depression Inventory After Treatment: Comparison Between Randomized Groups
Variable
Study (no. cohorts)
Teasdale et al. (2000; 8) Ma & Teasdale (2004; 4) Both (12)
Treatment (no. groups) MBCT (8) Control (8) MBCT (4) Control (4) MBCT (12) Control (12)
Time to relapse
No. participants 55 50 28 27 83 77
F ratio (significance) 0.731 (.646) 0.270 (.962) 0.945 (.435) 0.525 (.670) 0.684 (.749) 0.444 (.930)
IGC estimate 0.040 0.116 0.008 0.073 0.027 0.049
BDI after treatment
No. participants 48 47 28 24 76 71
F ratio (significance) 1.544 (0.160) 1.352 (.253) 1.337 (.286) 0.674 (.578) 0.934 (.514) 1.154 (.338)
IGC estimate 0.072 0.048 0.045 0.049 0.006 0.013
BDI after treatment—corrected for baseline
No. participants 48 45 28 24 76 69
F ratio (significance) 0.683 (.168) 1.447 (.216) 2.145 (.121) 1.018 (.406) 0.979 (.475) 1.183 (.135)
IGC estimate 0.041 0.053 0.222 0.004 0.002 0.015
Note. MBCT  mindfulness-based cognitive therapy; IGC  intragroup correlation; BDI  Beck Depression Inventory.
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seek to estimate IGC, the resulting variance inflation, and, thus, the
necessary sample size. Those implementing such trials should seek
to maximize the intrinsic therapeutic effect of group work while
they seek to minimize group effects on evaluation, in particular by
keeping individual responses personal and confidential. In analyz-
ing such trials, they should use multilevel models. In reporting
such trials, they should follow the extension of the CONSORT
statement to cluster randomized trials (Campbell, Elbourne, &
Altman, 2004).
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